KLTO‑202 is an experimental gene therapy that would deliver the instructions for a protein that may reduce inflammation and oxidative stress.

A noninvasive therapy delivering gentle spinal stimulation was shown to slow disease progression and extend survival in an ...

Clene is continuing to work with U.S. regulators on its plans to seek accelerated approval of CNM-Au8 for the treatment of ...

Neurizon Therapeutics has entered into a global licensing deal with Elanco Animal Health to advance the development of ...

A coalition of ALS patients and caregivers is petitioning the FDA to review available data on the stem cell therapy NurOwn ...

The FDA granted orphan drug designation to Sineugene Therapeutics' SNUG01, a first-in-class experimental gene therapy for ...

Klotho is advancing its ALS gene therapy candidate KLTO‑202 to the manufacturing phase, and is planning the first human ...

A Q&A with author and activist Mindy Uhrlaub, who shares how she is using her voice to raise awareness and support for the ...

Reflecting on a scary road rage incident reminds columnist Kristin Neva of the fragility of life. None of us is guaranteed tomorrow.

Columnist Dagmar Munn shares how she finds ways to keep her anxiety and ALS fears in check with a few simple responses.

As her husband's ALS journey extends, columnist Kristin Neva considers finally "settling in," so to speak, by securing a better bed.

A coalition of ALS patients and caregivers is petitioning the FDA to review available data on the stem cell therapy NurOwn (debamestrocel).